<DOC>
	<DOCNO>NCT00833690</DOCNO>
	<brief_summary>The purpose study determine safety tolerability inosine ability raise urate level blood cerebral spinal fluid individual early Parkinson disease . This determine whether appropriate proceed large study inosine 's ability modify rate disability progression PD .</brief_summary>
	<brief_title>Safety Urate Elevation Parkinson 's Disease</brief_title>
	<detailed_description>Background &amp; Rationale : Convergent epidemiological clinical observation identify urate - major antioxidant end product purine metabolism human - first molecular predictor risk progression typical Parkinson 's disease ( PD ) . Among 1600 early PD patient enrol prior clinical trial , baseline serum urate level high quintile ( i.e. , upper normal range ) display 40 % slow rate clinical ( disability ) progression compare baseline urate median ( p &lt; 0.000001 trend across quintiles ) . Similarly , amongst underwent serial SPECT brain scan change dopamine transporter ( DAT ) binding , high baseline serum urate level display slow rate radiographic progression ( loss striatal DAT ) . Moreover , urate level baseline cerebrospinal fluid ( CSF ) sample also correlate inversely rate clinical progression . Although link urate slow decline PD appear reproducible robust , critical question causality remain answered well-designed clinical trial . The biological plausibility neuroprotection urate strengthens rationale expedient pursuit trial . The availability establish pharmacological approach elevate urate make trial feasible . In particular , inosine , orally bioavailable , central nervous system ( CNS ) -penetrant purine precursor urate , offer practical strategy readily elevate serum urate , widely consume nutritional supplement , administer chronically several multi-year clinical trial multiple sclerosis . Before embark neuroprotection trial inosine PD , careful assessment safety , validity methodology approach PD patient warrant . Specific Aims : The main goal study determine whether inosine suitable phase III evaluation ability modify rate disability progression PD . Specific primary aim entail determination safety tolerability oral inosine , ability elevate urate level serum CSF ; selection optimal dose regimen . Secondary aim entail optimization possible phase III study design . Methods : A placebo-controlled double-blind dose-ranging randomize trial inosine conduct early PD . Ninety untreated subject diagnose idiopathic PD serum urate population mean ( ~6 mg/dL ) enrol 17 North American site randomize one three treatment group ( n=30 ) : 1 ) placebo , 2 ) inosine dose produce mild elevation serum urate , 3 ) inosine dose produce moderate elevation . Tolerability , validity ( urate elevation ) , dosage symptomatic efficacy assess 12 week treatment . Contingent adequate tolerability validity assess short-term analysis , study continue 2 year total duration 2 group ( placebo merge single inosine dose group ) original 3 assess long-term tolerability safety , focus main known risk urolithiasis gouty arthritis theoretical risk cardiovascular disease . Significance : This study determine whether phase III trial inosine potential neuroprotectant PD warrant . If , present study could shorten substantially lead time , optimization key design feature would enhance likelihood safety success .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Idiopathic PD least two cardinal sign PD ( rest tremor , bradykinesia , rigidity ) Currently take need treatment PD monoamine oxidaseB ( MAOB ) inhibitor Age 30 old time PD diagnosis Diagnosis PD make within past 3 year Serum urate ≤ 5.8 mg/dL initial screen History kidney stone , gout , stroke , heart attack History renal disease certain cardiovascular problem within past year Acidic urine ( pH ≤ 5.0 ) , uric acid , urate crystalluria screen Use certain medication include coenzyme Q , creatine , 50 IU vitamin E daily , 300 mg vitamin C daily . ( A standard daily multivitamin permit . ) Use antiPD medication target central nervous system dopamine transmission Known unstable medical psychiatric condition may compromise participation study Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Parkinson disease</keyword>
	<keyword>PD</keyword>
	<keyword>inosine</keyword>
	<keyword>urate</keyword>
	<keyword>uric acid</keyword>
	<keyword>cerebrospinal fluid</keyword>
</DOC>